

Triggerable Oxygen Nanobubbles for Drug Delivery, Diagnosis, and Enhanced Survival

Track Code: 2015-IRUD-66920

Categories:

- Biomedical Engineering

Keywords:

- Biomedical Engineering
- Diagnostic Imaging
- Drug Delivery
- Imaging
- Medical Diagnostics
- Ultrasound Imaging

Ultrasound has a broad clinical utility in prostate cancer diagnosis because of its diagnostic capabilities, ease of use, portability, and ability to reveal fluid flow and structure of anatomy in vivo. Several commercial ultrasound contrast agents exist, but are synthesized using fluorinated gases or air and have sizes in the micron range. Past efforts have at most synthesized ~500 nm-sized particles and primarily functioned as a contrast agent. These large particles fail to take advantage of the enhanced permeability and retention (EPR) effect.

Researchers at Purdue University have capitalized on the broad clinical utility of ultrasound. This technology is the first nanosized oxygen- and cargo-bearing bubbles that can be tuned to first image at a low intensity and selectively release cargo upon an ultrasound trigger at a higher intensity.

Advantages:

-Enhanced permeability and retention inside tumor vasculature.

- -Controlled drug release
- -Avoids immune system response.
- -Transport of material through the encapsulating layer.

Potential Applications: -Pharmaceutical industry -Medical/Healthcare -Cancer drug delivery and diagnosis

-Therapy for cancerous tumors

People:

Irudayaraj, Joseph (Project leader)Bhandari, Pushpak N

Intellectual Property:

Application Date: March 7, 2018 Type: CIP-Patent Country of Filing: United States Patent Number: 10,670,581 Issue Date: June 2, 2020

Application Date: October 2, 2015 Type: Utility Patent Country of Filing: United States Patent Number: 9,968,692 Issue Date: May 15, 2018

Application Date: April 17, 2020 Type: DIV-Gov. Funding Country of Filing: United States Patent Number: (None) Issue Date: (None)

Application Date: April 14, 2015 Type: Provisional-Patent Country of Filing: United States Patent Number: (None) Issue Date: (None)

Application Date: November 5, 2014 Type: Provisional-Patent Country of Filing: United States Patent Number: (None) Issue Date: (None)

Application Date: October 2, 2014 Type: Provisional-Patent Country of Filing: United States Patent Number: (None) Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486 Email: otcip@prf.org